Stroke Trials Registry

PROGRESS
Perindopril Protection Against Recurrent Stroke Study

Principal Investigator
John Chalmers

PI Address
The University of Sydney, Australia.

Contact Address
R. Currie, Clinical Trials Research Unit, University of Auckland, Private Bag 92019, Auckland, New Zealand.

Sponsor

Study Size Actual:	6105
Centers Actual:	172
Max Time from onset:	5 Years
Follow-up Duration:	5 Years

Status:
Trial complete. Results published in September 2001.

Purpose:
To compare the angiotensin-converting enzyme (ACE) inhibitor perindopril, alone or in combination with the diuretic indapamide, to placebo in the secondary prevention of stroke and other major cardiovascular events.

Interventions:

Antihypertensives
This category includes all BP lowering drugs in stroke prevention trials

Perindopril
Antihypertensive; angiotensin converting enzyme (ACE) inhibitor

Location(s):
Australia, Belgium, France, Italy, Japan, New Zealand, People’s Republic of China, Republic of Ireland, Sweden, United Kingdom

Year Started: 1996

Year Finished: 1997

Year Presented: 2001

Year Published: 2001

Design:
Randomized, double-blind, placebo-controlled, international, trial of 6105 patients at 172 centers.

Inclusion Criteria
Normotensive or hypertensive patients with a history of stroke or transient cerebral ischemia within the previous 5 years.

Patient Involvement:
Patients were randomly assigned to treatment with the ACE inhibitor perindopril 4 mg or placebo, plus the diuretic indapamide (for individuals in whom it was not considered to be definitely indicated or contraindicated) or placebo.

Primary Outcome:
Total number of strokes defined by WHO criteria.

Secondary Outcome:
Fatal and disabling strokes, total number of cardiovascular events and deaths, cognitive function, disability, and dependency. Mean follow-up is 3 years.

Results:
Preliminary results: Perindopril group had a 28% relative risk reduction (95% CI 17-38%, p<.0001) in primary endpoint (total strokes).

Web Links and Publications:

Effects of a Perindopril-Based Blood Pressure Lowering Regimen on the Risk of Recurrent Stroke According to Stroke Subtype and Medical History
Stroke 2004;35:116-121.

Effects of a Perindopril-Based Blood Pressure-Lowering Regimen on Disability and Dependency in 6105 Patients With Cerebrovascular Disease.
Stroke 2003;34:xx-xx.

The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): Clinical Implications for Older Patients with Cerebrovascular Disease.
Drugs Aging 2003;20(4):241-51

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.
Lancet. 2001 Sep 29;358(9287):1033-41.

PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee.
J Hypertens Suppl 2000 May;18(1):S13-9.

PROGRESS - Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Progress Management Committee.
J Hypertens 1999 Nov;17(11):1647-55.

PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. PROGRESS Management Committee.
J Hum Hypertens 1998 Sep;12(9):627-9

Blood pressure lowering for the prevention of cognitive decline in patients with cerebrovascular disease. PROGRESS Management Committee. Perindopril Protection Against Recurrent Stroke Study.
Clin Exp Hypertens 1997 Jul-Aug;19(5-6):843-55

Blood pressure lowering in patients with cerebrovascular disease: results of the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) pilot phase.
Clin Exp Pharmacol Physiol 1996 May;23(5):444-6

PROGRESS (perindopril protection against recurrent stroke study): rationale and design. PROGRESS Management Committee.
J Hypertens 1995 Dec;13(12 Pt 2):1869-73

This information last updated on: 9/2/2008

Reviewed on: 09/02/2008.

UID: 65